| Heart disease and stroke statistics—2016 update: a report from the American Heart Association D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ... circulation 133 (4), e38-e360, 2016 | 76143* | 2016 |
| Dabigatran versus warfarin in patients with atrial fibrillation SJ Connolly, MD Ezekowitz, S Yusuf, J Eikelboom, J Oldgren, A Parekh, ... New England journal of medicine 361 (12), 1139-1151, 2009 | 14291 | 2009 |
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators New England Journal of Medicine 345 (7), 494-502, 2001 | 8623 | 2001 |
| Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines J Ansell, J Hirsh, E Hylek, A Jacobson, M Crowther, G Palareti Chest 133 (6), 160S-198S, 2008 | 7762* | 2008 |
| Evidence-based medicine: a new approach to teaching the practice of medicine G Guyatt, J Cairns, D Churchill, D Cook, B Haynes, J Hirsh, J Irvine, ... Jama 268 (17), 2420-2425, 1992 | 6526 | 1992 |
| American Heart Association/American College of Cardiology foundation guide to warfarin therapy J Hirsh, V Fuster, J Ansell, JL Halperin Circulation 107 (12), 1692-1711, 2003 | 4707 | 2003 |
| Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety J Hirsh, TE Warkentin, SG Shaughnessy, SS Anand, JL Halperin, ... Chest 119 (1), 64S-94S, 2001 | 3318* | 2001 |
| A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods R Gosselin, JT Owings, RH White, R Hutchinson, J Branch, K Mahackian, ... Thrombosis and haemostasis 83 (05), 698-703, 2000 | 3280 | 2000 |
| Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin TE Warkentin, MN Levine, J Hirsh, P Horsewood, RS Roberts, M Gent, ... New England Journal of Medicine 332 (20), 1330-1336, 1995 | 3099 | 1995 |
| Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range J Hirsh, JE Dalen, DR Anderson, L Poller, H Bussey, J Ansell, D Deykin Chest 119 (1), 8S-21S, 2001 | 3026* | 2001 |
| Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer PS Wells, DR Anderson, M Rodger, JS Ginsberg, C Kearon, M Gent, ... Thrombosis and haemostasis 83 (03), 416-420, 2000 | 2355 | 2000 |
| The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction GUSTO Angiographic Investigators New England Journal of Medicine 329 (22), 1615-1622, 1993 | 2141 | 1993 |
| Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy C Patrono, B Coller, GA FitzGerald, J Hirsh, G Roth Chest 126 (3), 234S-264S, 2004 | 2106* | 2004 |
| Heparin J Hirsh New England Journal of Medicine 324 (22), 1565-1574, 1991 | 1988* | 1991 |
| Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events JW Eikelboom, J Hirsh, JI Weitz, M Johnston, Q Yi, S Yusuf Circulation 105 (14), 1650-1655, 2002 | 1653 | 2002 |
| A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis M Levine, M Gent, J Hirsh, J Leclerc, D Anderson, J Weitz, J Ginsberg, ... New England Journal of Medicine 334 (11), 677-681, 1996 | 1635 | 1996 |
| A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism C Kearon, M Gent, J Hirsh, J Weitz, MJ Kovacs, DR Anderson, AG Turpie, ... New England Journal of Medicine 340 (12), 901-907, 1999 | 1492 | 1999 |
| Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. JI Weitz, M Hudoba, D Massel, J Maraganore, J Hirsh The Journal of clinical investigation 86 (2), 385-391, 1990 | 1450 | 1990 |
| Use of a clinical model for safe management of patients with suspected pulmonary embolism PS Wells, JS Ginsberg, DR Anderson, C Kearon, M Gent, AG Turpie, ... Annals of internal medicine 129 (12), 997-1005, 1998 | 1449 | 1998 |
| Low molecular weight heparin FHKFH Kids | 1295 | 1992 |
